[1] Ebrahimi M, Akbari Asbagh F, Davari Tanha F, Pakniat H, Feizabad E, Rasouli Y. Co-treatment of gonadotropin and letrozole in infertile women with endometriosis: A double-blind randomized clinical trial. Int J Reprod BioMed 2022; 20: 483–490.

[2] Vannuccini S, Clemenza S, Rossi M, Petraglia F. Hormonal treatments for endometriosis: The endocrine background. Rev Endocr Metab Disord 2022; 23: 333–355.

[3] Khashchenko EP, Uvarova EV, Chuprynin VD, Pustynnikova MY, Fatkhudinov TK, Elchaninov AV, et al. Pelvic pain, mental health and quality of life in adolescents with endometriosis after surgery and dienogest treatment. J Clin Med 2023; 12: 2400.

[4] Sutrisno S, Firdaus WA. Efficacy of dienogest on pelvic pain and dyspareunia: Comprehensive meta-analysis and systematic review. Asian J Health Res 2023; 2: 89–95.

[5] Lamceva J, Uljanovs R, Strumfa I. The main theories on the pathogenesis of endometriosis. Int J Mol Sci 2023; 24: 4254.

[6] Wang P-H, Yang S-T, Chang W-H, Liu C-H, Lee F-K, Lee W-L. Endometriosis: Part I. Basic concept. Taiwan J Obstet Gynecol 2022; 61: 927–934.

[7] Carneiro MM. Deciding on the appropriate pharmacotherapy for the treatment of endometriosis. Exp Opin Pharmacother 2023; 24: 1–5.

[8] Kalaitzopoulos DR, Samartzis N, Kolovos GN, Mareti E, Samartzis EP, Eberhard M, et al. Treatment of endometriosis: A review with comparison of 8 guidelines. BMC Women’s Health 2021; 21: 397.

[9] Mariani LL, Mancarella M, Fuso L, Baino S, Biglia N, Menato G. Endometrial thickness in the evaluation of clinical response to medical treatment for deep infiltrating endometriosis: A retrospective study. Arch Gynecol Obstet 2021; 303: 161–168.

[10] Surrey ES. GnRH agonists in the treatment of symptomatic endometriosis: A review. F S Rep 2023; 4 (Suppl.): 40–45.

[11] Veth VB, van de Kar MM, Duffy JM, van Wely M, Mijatovic V, Maas JW. Gonadotropin-releasing hormone analogues for endometriosis. Cochrane Database Syst Rev 2023; 6: CD014788.

[12] Bizzarri N, Remorgida V, Leone Roberti Maggiore U, Scala C, Tafi E, Ghirardi V, et al. Dienogest in the treatment of endometriosis. Exp Opin Pharmacother 2014; 15: 1889–1902.

[13] Moehner S, Becker K, Lange JA, von Stockum S, Serrani M, Heinemann K. Long-term treatment of endometriosis with dienogest: Real-world results from the VIPOS study. J Endometriosis Pelvic Pain Disord 2021; 13: 104–110.

[14] Granese R, Perino A, Calagna G, Saitta S, De Franciscis P, Colacurci N, et al. Gonadotrophin-releasing hormone analogue or dienogest plus estradiol valerate to prevent pain recurrence after laparoscopic surgery for endometriosis: A multi-center randomized trial. Acta Obstet Gynecol Scand 2015; 94: 637–645.

[15] Murji A, Biberoğlu K, Leng J, Mueller MD, Römer T, Vignali M, et al. Use of dienogest in endometriosis: A narrative literature review and expert commentary. Curr Med Res Opin 2020; 36: 895–907.

[16] Takaesu Y, Nishi H, Kojima J, Sasaki T, Nagamitsu Y, Kato R, et al. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis. J Obstet Gynaecol Res 2016; 42: 1152–1158.

[17] Techatraisak K, Hestiantoro A, Soon R, Banal-Silao MJ, Kim M-R, Seong SJ, et al. Impact of long-term dienogest therapy on quality of life in Asian women with endometriosis: The prospective non-interventional study ENVISIOeN. Reprod Sci 2022; 29: 1157–1169.

[18] Yu EH, Joo JK. Commentary on the new 2022 European Society of Human Reproduction and Embryology (ESHRE) endometriosis guidelines. Clin Exp Reprod Med 2022; 49: 219.

[19] Li R-R, Xi Q, Tao L, Sheng W, Zhao C-C, Wu Y-J. A systematic review and bayesian analysis of the adverse effects of dienogest. BMC Pharmacol Toxicol 2024; 25: 43.

[20] Wu H, Liu J-J, Ye S-T, Liu J, Li N. Efficacy and safety of dienogest in the treatment of deep infiltrating endometriosis: A meta-analysis. Eur J Obstet Gynecol Reprod Biol 2024; 297: 40–49.

[21] Osuga Y, Hayashi K, Kanda S. Long-term use of dienogest for the treatment of primary and secondary dysmenorrhea. J Obstet Gynaecol Res 2020; 46: 606–617.

[22] Huang Y, Zhang D, Zhang L, Zhou Y, Peng C. Clinical efficacy of dienogest against endometriomas with a maximum diameter of ≥ 4 cm. Ann Med 2024; 56: 2402942.

[23] Muzii L, Di Tucci C, Galati G, Carbone F, Palaia I, Bogani G, et al. The efficacy of dienogest in reducing disease and pain recurrence after endometriosis surgery: A systematic review and meta-analysis. Reprod Sci 2023; 30: 3135–3143.

[24] Ozaki R, Kumakiri J, Jinushi M, Ikuma S, Murakami K, Kawasaki Y, et al. Comparison of effect of preoperative dienogest and gonadotropin-releasing hormone agonist administration on laparoscopic cystectomy for ovarian endometriomas. Arch Gynecol Obstet 2020; 302: 969–976.

[25] Barra F, Scala C, Leone Roberti Maggiore U, Ferrero S. Long-term administration of dienogest for the treatment of pain and intestinal symptoms in patients with rectosigmoid endometriosis. J Clin Med 2020; 9: 154.

[26] Seo Y-S, Yuk J-S, Cho Y-K, Shin J-Y. Dienogest and the risk of reoperation in endometriosis. J Pers Med 2021; 11: 924